ITOG's first clinical trial has reached 50% of patient accrual. This multi-institution clinical trial, led by Dr. Manisha H. Shah from Ohio State University,examines whether patients who had progression of their thyroid cancer on a VEGFR inhibitor benefit from treatment with Cabozantinib.
ITOG opened its first clinical trial one year ago for treatment of differentiated thyroid cancer. NCI9312/OSU12154/RU241210I is an investigator-initiated, multicenter, open label, phase II trial of Cabozantinib in patients with radioiodine-refractory, differentiated thyroid cancer (DTC), who progressed on first-line therapy with a VEGFR antagonist. ITOG’s first clinical trial is coordinated by the Academic and Community Cancer Research United (ACCRU) and is funded by Cancer Therapy Evaluation Program (CTEP) of National Cancer Institute (NCI). Additional funding for the clinical trial and correlative science is provided by ITOG, which is a 501(c)(3) tax-exempt public charity. ITOG’s mission is to catalyze a cure for thyroid cancer.
Led by Ohio State University Comprehensive Cancer Center, this study is open at Massachusetts General Hospital, Mayo Clinic (Jacksonville and Rochester), MD Anderson Cancer Center, Roswell Park Cancer Institute and University of Chicago.
Cabozantinib is an oral multikinase inhibitor targeting several angiogenic proteins such as VEGFR, PDGFR, c-met as well as RET kinase. It was recently approved by the Food and Drug Administration of United States for patients with progressive medullary thyroid cancer. ITOG is testing this drug for its use in a 2nd line setting for patients with DTC who progress on first line VEGFR targeted therapy. Given that c-met is thought to be critical in causing failure of VEGFR targeted therapy, cabozantinib is chosen for testing in 2nd line setting due to its unique activity against c-met. During the trial, the study drug will be administered orally once daily until cancer progression or intolerance. The study will also examine if this drug is effective against bony metastasis.
Eligible patients are required to have locally advanced or metastatic, radioiodine-refractory DTC, measurable disease, progression on exactly one line of prior VEGFR-targeted therapy (including but not limited to sorafenib, sunitinib, vandetanib, pazopanib, or lenvatinib) within 24 weeks prior to study entry. More information related to trial is available at http://clinicaltrials.gov/ct2/show/NCT01811212?term=cabozantinib+in+thyroid&rank=2
For questions related to trial please contact Manisha H. Shah, MD at 614-293-4680 or email@example.com